Cloudphar Pharmaceuticals

Cloudphar Pharmaceuticals is a biopharmaceutical joint venture between China's Tasly Holding Group and France's Pharnext, focused on the modernization of Traditional Chinese Medicine (TCM) and the development of synergistic drug combinations. The company leverages advanced artificial intelligence, network pharmacology, and big data through its proprietary LTM-TCM database to identify bioactive compounds and predict therapeutic mechanisms. Cloudphar's R&D efforts span neurodegenerative diseases, cardiovascular conditions, and infectious diseases, utilizing a "network-target, multiple-component" approach to bridge the gap between traditional herbal remedies and modern evidence-based medicine. The company is also responsible for developing Pharnext's Pleotherapy pipeline, including candidates for Charcot-Marie-Tooth disease and Alzheimer's, within the Greater China market. By integrating computational biology with clinical evidence, Cloudphar aims to transform complex traditional formulas into standardized, high-quality pharmaceutical products.